Phase I open label study of a subcutaneous (SC) form of CT-P13 in healthy volunteers

Trial Profile

Phase I open label study of a subcutaneous (SC) form of CT-P13 in healthy volunteers

Completed
Phase of Trial: Phase I

Latest Information Update: 03 Nov 2017

At a glance

  • Drugs Infliximab (Primary)
  • Indications Ankylosing spondylitis; Crohn's disease; Plaque psoriasis; Psoriatic arthritis; Rheumatoid arthritis; Ulcerative colitis
  • Focus Adverse reactions
  • Most Recent Events

    • 03 Nov 2017 New trial record
    • 29 Oct 2017 According to a Celltrion media release, data were presented at the 25th United European Gastroenterology Week Congress.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top